This article provides a comprehensive summary of the knowledge gained from recent neoadjuvant trials conducted with agents targeting HER2, and will put them into perspective with current treatment recommendations from American and European guidelines.
This article addresses some of the most common major challenges in oncologist-patient communication with a nuanced approach to the concepts of autonomy, paternalism, and culture. 
We have entered a period of accelerated drug development and optimism in the care of advanced prostate cancer. The treatment paradigm for these patients is rapidly evolving, with future study needed to define the optimal sequencing and potential combinations of these new agents.
The aim of this review is twofold: to summarize descriptions of the clinical presentation provided in published series in order to help clinicians recognize and treat patients, and to discuss diagnostic difficulties faced by hematopathologists when dealing with these lesions and others in the differential diagnosis that must be distinguished from one another.
Muscle-invasive bladder cancer is an aggressive and potentially lethal disease. Integration of multimodal therapies, improved surgical techniques, and utilization of targeted agents has tremendously improved outcomes.
The active constituent of green tea extract is EGCG, which accounts for 40% of its total polyphenol content. Regular consumption of green tea may reduce the risk of hypertension and positively affect mood. 
This review will examine agents with potential activity in the palliation and treatment of skeletal metastases of PCa, and will weigh the clinical-outcomes evidence for and against their broad use.
While ONCOLOGY has continued to evolve along with the field of oncology—for example, it now addresses critical issues of science and socioeconomics—it has remained true to the founding principles. Perhaps largely for this reason, the journal continues to be widely read across the entire oncology community.
The past year in oncology was highlighted by the continuation of breakthroughs in targeted therapies—with new treatments receiving US Food and Drug Administration (FDA) approval for non–small-cell lung cancer (NSCLC), lymphoma, and melanoma.
Treatment for patients with locally advanced, resectable rectal cancer has clearly evolved, with significant refinements in preoperative assessment, surgical technique, and use of preoperative CMT. 
Two recent reports show that the prognosis of MDS patients after secondary failure of hypomethylating drugs is poor, and switching from one failing hypomethylating drug to another cannot induce clinically significant responses.
As insurers, clinicians and the U.S. government attempt to slow the increasing rise of health care costs, many experts have identified the tool entitled “clinical pathways” as a solution. Oncologists who adhere to such pathways are thought to improve patient care and reduce expenses.
Nationally, the number of drug shortages has tripled since 2005. Other generic drug shortages in our clinic have included paclitaxel, leucovorin, and doxorubicin. We have had limited ability to order fluorouracil (5-FU) and mitomycin.
The goal of this activity is to clarify challenging treatment issues of HER2+ breast cancer including incorporation of predictive and prognostic biomarker tests and evidence-based data into practice when determining individualized strategies that improve patient survival and quality of life.
These interactive CME activities are offered to physicians and other healthcare professionals without charge by CME. 
CancerNetwork presents exclusive coverage from the American Society of Hematology (ASH) annual meeting, including a podcast, and reports on the top stories from San Diego.
CancerNetwork presents exclusive coverage from the annual San Antonio Breast Cancer Symposium. This year's coverage includes a podcast with Kent Osborne plus reports of the top stories from this year's meeting.
The European Multidisciplinary Cancer Congress brings together the European oncology community and is a joint effort between the ESMO, ECCO, and ESTRO.
This year's coverage of the annual meeting of the American Society of Clinical Oncology (ASCO) includes podcasts, videos, and write-ups of the most important information to come out of this year's event.
- Head and Neck Tumors
- 46-Year-Old Woman Presents With Difficulty in Ambulation, and Swelling and Discoloration of Both Eyelids
- Optimizing Outcomes of Advanced Prostate Cancer: Drug Sequencing and Novel Therapeutic Approaches
- A 28-Year-Old Woman Presents With a Long-Standing History of Intermittently Painful “Bumps” on Both Her Shoulders and Upper Back
- Controversies in Oncologist-Patient Communication: A Nuanced Approach to Autonomy, Culture, and Paternalism
|
TOPIC INDEX
JOB LISTINGS
Post a job
Powered by SearchMedica Jobs
CONNECT WITH US
|
|
|||||||||||||||||||||||||
CancerNetwork |
CME LLC |
ConsultantLive |
Diagnostic Imaging |
Musculoskeletal Network |
OBGYN.net |
PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
© 1996 - 2012 UBM Medica LLC, a
UBM company
Privacy Statement -
Terms of Service -
Advertising Information -
Editorial Policy Statement -
UBM Medica Network Privacy Policy